Sökning: onr:"swepub:oai:gup.ub.gu.se/120176" > A novel polymorphis...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05151naa a2200781 4500 | |
001 | oai:gup.ub.gu.se/120176 | |
003 | SwePub | |
008 | 240910s2009 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:119596512 | |
009 | oai:DiVA.org:uu-127425 | |
024 | 7 | a https://gup.ub.gu.se/publication/1201762 URI |
024 | 7 | a https://doi.org/10.1111/j.1365-2125.2009.03516.x2 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1195965122 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1274252 URI |
040 | a (SwePub)gud (SwePub)kid (SwePub)uu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Mukonzo, Jackson K4 aut |
245 | 1 0 | a A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. |
264 | c 2009-08-07 | |
264 | 1 | b Wiley,c 2009 |
520 | a AIMS: Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim was to develop an integrated population pharmacokinetic/pharmacogenetic model and investigate the impact of genetic variations, sex, demographic and biochemical variables on single-dose efavirenz pharmacokinetics among Ugandan subjects, using NONMEM. METHODS: Efavirenz plasma concentrations (n = 402) from 121 healthy subjects were quantified by high-performance liquid chromatography. Subjects were genotyped for 30 single nucleotide polymorphisms (SNPs), of which six were novel SNPs in CYP2B6, CYP3A5 and ABCB1. The efavirenz pharmacokinetics was described by a two-compartment model with zero- followed by first-order absorption. RESULTS: Apparent oral clearance (95% confidence interval) was 4 l h l(-1) (3.5, 4.5) in extensive metabolizers. In the final model, incorporating multiple covariates, statistical significance was found only for CYP2B6*6 and CYP2B6*11 on apparent oral clearance as well as ABCB1 (rs3842) on the relative bioavailability. Subjects homozygous for CYP2B6*6 (G516T, A785G) and *11 displayed 21 and 20% lower apparent oral clearance, respectively. Efavirenz relative bioavailability was 26% higher in subjects homozygous for ABCB1 (rs3842). The apparent peripheral volume of distribution was twofold higher in women compared with men. CONCLUSIONS: The model identified the four factors CYP2B6*6, CYP2B6*11, a novel variant allele in ABCB1 (rs3842) and sex as major predictors of efavirenz plasma exposure in a healthy Ugandan population after single-dose administration. Use of mixed-effects modelling allowed the analysis and integration of multiple pharmacogenetic and demographic covariates in a pharmacokinetic population model. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a Adult | |
653 | a African Continental Ancestry Group | |
653 | a genetics | |
653 | a Anti-HIV Agents | |
653 | a pharmacokinetics | |
653 | a Benzoxazines | |
653 | a pharmacokinetics | |
653 | a Dose-Response Relationship | |
653 | a Drug | |
653 | a Female | |
653 | a Humans | |
653 | a Male | |
653 | a Models | |
653 | a Biological | |
653 | a Models | |
653 | a Genetic | |
653 | a Polymorphism | |
653 | a Genetic | |
653 | a genetics | |
653 | a Sex Factors | |
653 | a Uganda | |
653 | a Young Adult | |
653 | a ABCB1 | |
653 | a PHARMACY | |
700 | 1 | a Röshammar, Daniel,d 1979u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology4 aut0 (Swepub:gu)xroshd |
700 | 1 | a Waako, Paul4 aut |
700 | 1 | a Andersson, Maria4 aut |
700 | 1 | a Fukasawa, Takashi4 aut |
700 | 1 | a Milani, Liliu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut |
700 | 1 | a Svensson, Jan Olof4 aut |
700 | 1 | a Ogwal-Okeng, Jasper4 aut |
700 | 1 | a Gustafsson, Lars Lu Karolinska Institutet4 aut |
700 | 1 | a Aklillu, Eleniu Karolinska Institutet4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi4 org |
773 | 0 | t British journal of clinical pharmacologyd : Wileyg 68:5, s. 690-9q 68:5<690-9x 1365-2125x 0306-5251 |
856 | 4 | u https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2009.03516.x |
856 | 4 8 | u https://gup.ub.gu.se/publication/120176 |
856 | 4 8 | u https://doi.org/10.1111/j.1365-2125.2009.03516.x |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:119596512 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-127425 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy